ClinicalTrials.gg
CompletedNCT01782495CORAL-IUpdated Nov 7, 2017Results posted

A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients

A Phase 2 interventional study of ombitasvir/paritaprevir/ritonavir and dasabuvir and ombitasvir/paritaprevir/ritonavir in Chronic Hepatitis C Infection, sponsored by AbbVie. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-11-07.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
129
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and efficacy of ABT-450/r/ABT-267 with or without ABT-333 and with or without ribavirin (RBV) in adult liver or renal transplant recipients with hepatitis C virus (HCV) genotype 1 or 4 (GT1 or GT4) infection.

02

Conditions studied

  • Chronic Hepatitis C Infection

Keywords

  • Hepatitis C Genotype 4
  • Chronic Hepatitis
  • Interferon-Free
  • Hepatitis C Virus (HCV)
  • Renal Transplant
  • Liver Transplant
  • Hepatitis C Genotype 1
03

In context

Hepatitis, Chronic

83 studies on the registry are indexed under Hepatitis, Chronic; 10 are open to participants now.

This study's enrollment of 129 is above the median of 84 across 59 interventional studies indexed under Hepatitis, Chronic.

Browse Hepatitis, Chronic studies →

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, at least 18 years of age at the time of screening.
  • Currently taking an regimen based on either tacrolimus or cyclosporine. such as prednisone or prednisolone are permitted as components of the immunosuppressant regimen providing the dose is not more than 10 mg/day.
  • virus (HCV) interferon (IFN) therapy treatment-naïve or -experienced, either pre- or post-liver or renal transplant.
  • Screening HCV genotype testing indicating infection with genotype 1 or 4 (GT1 or GT4) only.

Exclusion criteria

Exclusion Criteria:

  • Use of everolimus or sirolimus as part of the regimen within 2 months of Screening Visit.
  • Use of any medications for use with the study regimen as well as those that are contraindicated for use with either ritonavir or ribavirin within 2 weeks prior to study drugs administration or 10 half-lives (if known), whichever is longer.
  • Positive test result for surface antigen (HBsAg) or anti- antibody (HIV Ab).
  • Documented history of post-transplant complications directly involving the hepatic or renal vasculature as appropriate to the organ transplanted, e.g., thrombosis of the portal vein, the hepatic artery and/or hepatic vein.
  • abnormalities, other than infection, in a subject post-transplant based upon the medical history, physical examination, vital signs, laboratory profile and a 12-lead (ECG) that make the subject an unsuitable candidate for this study in the opinion of the investigator.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
129 participants (actual)

Study arms

  • Experimental
    Arm A

    Liver transplant recipients with HCV genotype 1 infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 24 weeks.

    Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir · Drug: ribavirin

  • Experimental
    Arm B

    Liver transplant recipients with HCV genotype 1a or genotype 1b (dependent on prior treatment experience and response) infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 24 weeks.

    Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir · Drug: ribavirin

  • Experimental
    Arm C

    Liver transplant receipts with HCV genotype 1b infection who were treatment naïve or prior responders to interferon treatment without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 24 weeks.

    Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir

  • Experimental
    Arm D

    Liver transplant recipients with HCV genotype 1a infection with Child Pugh A cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (dosed 1,000 or 1,200 mg daily divided twice a day) for 24 weeks.

    Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir · Drug: ribavirin

  • Experimental
    Arm E

    Liver transplant recipients with HCV genotype 1b infection with Child Pugh A cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.

    Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir · Drug: ribavirin

  • Experimental
    Arm F

    Liver transplant recipients with HCV genotype 1a infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.

    Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir · Drug: ribavirin

  • Experimental
    Arm G

    Liver transplant recipients with HCV genotype 1b infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 12 weeks.

    Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir

  • Experimental
    Arm H

    Renal transplant recipients with HCV genotype 1a infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.

    Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir · Drug: ribavirin

  • Experimental
    Arm I

    Renal transplant recipients with HCV genotype 1b infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 12 weeks.

    Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir

  • Experimental
    Arm J

    Liver transplant recipients with HCV genotype 4 infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.

    Drug: ombitasvir/paritaprevir/ritonavir · Drug: ribavirin

  • Experimental
    Arm K

    Liver transplant recipients with HCV genotype 4 infection with Child Pugh A cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 24 weeks.

    Drug: ombitasvir/paritaprevir/ritonavir · Drug: ribavirin

Interventions

  • Drugombitasvir/paritaprevir/ritonavir and dasabuvir

    Drug pages: Ombitasvir · Paritaprevir · Ritonavir · Dasabuvir

    Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet

    Also known as: Viekira Pak, paritaprevir also known as ABT-450, ombitasvir also known as ABT-267, dasabuvir also known as ABT-333

  • Drugombitasvir/paritaprevir/ritonavir

    Drug page: Ombitasvir/Paritaprevir/Ritonavir

    Tablet; ombitasvir coformulated with paritaprevir and ritonavir

    Also known as: TECHNIVIE, paritaprevir also known as ABT-450, ombitasvir also known as ABT-267

  • tablet

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)

    SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 12 weeks after the last dose of study drug. Participants with missing data after backward imputation were imputed as nonresponders.

    Time frame: 12 weeks after the last actual dose of study drug

Secondary outcomes

  1. Percentage of Participants With Sustained Virologic Response 24 Weeks Post-treatment (SVR24)

    SVR24 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 24 weeks after the last dose of study drug. Participants with missing data after backward imputation were imputed as nonresponders.

    Time frame: 24 weeks after the last actual dose of study drug

  2. Percentage of Participants With On-treatment Virologic Failure

    On-treatment virologic failure was defined as confirmed increase of \> 1 log(subscript)10(subscript) IU/mL above the lowest value post-baseline HCV RNA during treatment, or confirmed HCV RNA ≥ LLOQ at any point during treatment after HCV RNA \< LLOQ, or HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks (≥ 36 days) of treatment.

    Time frame: Up to 12 weeks (for 12-week treatment) or 24 weeks (for 24-week treatment)

  3. Percentage of Participants With Post-treatment Relapse

    Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA levels \< LLOQ at the end of treatment.

    Time frame: From the end of treatment through 12 weeks after the last dose of study drug

07

Results

Posted Nov 7, 2017

Participant flow

Participant flow — Overall Study
MilestoneArm AArm BArm CArm DArm EArm FArm GArm HArm IArm JArm K
Started3427134222129321
Completed3426134222126321
Not completed01000003000
Withdrew: Adverse event00000002000
Withdrew: Withdrew consent01000001000

Outcome measures

PrimaryPercentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)

SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 12 weeks after the last dose of study drug. Participants with missing data after backward imputation were imputed as nonresponders.

Time frame:
12 weeks after the last actual dose of study drug
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
percentage of participantsArm AArm BArm CArm DArm EArm FArm GArm HArm IArm JArm K
Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)97.1 (85.1 to 99.5)96.3 (81.7 to 99.3)100 (77.2 to 100.0)100 (51.0 to 100.0)100 (34.2 to 100.0)95.5 (78.2 to 99.2)100 (75.8 to 100.0)66.7 (35.4 to 87.9)100 (43.9 to 100.0)100 (34.2 to 100.0)100 (20.7 to 100.0)
SecondaryPercentage of Participants With Sustained Virologic Response 24 Weeks Post-treatment (SVR24)

SVR24 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 24 weeks after the last dose of study drug. Participants with missing data after backward imputation were imputed as nonresponders.

Time frame:
24 weeks after the last actual dose of study drug
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virologic Response 24 Weeks Post-treatment (SVR24)
percentage of participantsArm AArm BArm CArm DArm EArm FArm GArm HArm IArm JArm K
Percentage of Participants With Sustained Virologic Response 24 Weeks Post-treatment (SVR24)97.1 (85.1 to 99.5)96.3 (81.7 to 99.3)100 (77.2 to 100.0)100 (51.0 to 100.0)100 (34.2 to 100.0)95.5 (78.2 to 99.2)100 (75.8 to 100.0)66.7 (35.4 to 87.9)100 (43.9 to 100.0)100 (34.2 to 100.0)100 (20.7 to 100.0)
SecondaryPercentage of Participants With On-treatment Virologic Failure

On-treatment virologic failure was defined as confirmed increase of \> 1 log(subscript)10(subscript) IU/mL above the lowest value post-baseline HCV RNA during treatment, or confirmed HCV RNA ≥ LLOQ at any point during treatment after HCV RNA \< LLOQ, or HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks (≥ 36 days) of treatment.

Time frame:
Up to 12 weeks (for 12-week treatment) or 24 weeks (for 24-week treatment)
Reported as:
Number · percentage of participants
Percentage of Participants With On-treatment Virologic Failure
percentage of participantsArm AArm BArm CArm DArm EArm FArm GArm HArm IArm JArm K
Percentage of Participants With On-treatment Virologic Failure0 (0.0 to 10.2)3.7 (0.7 to 18.3)0 (0.0 to 22.8)0 (0.0 to 49.0)0 (0.0 to 65.8)0 (0.0 to 14.9)0 (0.0 to 24.2)0 (0.0 to 29.9)0 (0.0 to 56.1)0 (0.0 to 65.8)0 (0.0 to 79.3)
SecondaryPercentage of Participants With Post-treatment Relapse

Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA levels \< LLOQ at the end of treatment.

Time frame:
From the end of treatment through 12 weeks after the last dose of study drug
Reported as:
Number · percentage of participants
Percentage of Participants With Post-treatment Relapse
percentage of participantsArm AArm BArm CArm DArm EArm FArm GArm HArm IArm JArm K
Percentage of Participants With Post-treatment Relapse3.0 (0.5 to 15.3)0 (0.0 to 12.9)0 (0.0 to 24.2)0 (0.0 to 49.0)0 (0.0 to 65.8)4.8 (0.8 to 22.7)0 (0.0 to 24.2)0 (0.0 to 39.0)0 (0.0 to 56.1)0 (0.0 to 65.8)0 (0.0 to 79.3)

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from first dose of study drug until 30 days after the last dose of study drug (up to 28 weeks).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ARM A0/34 (0%)2/34 (5.9%)33/34 (97.1%)
ARM B0/27 (0%)1/27 (3.7%)27/27 (100%)
ARM C0/13 (0%)0/13 (0%)12/13 (92.3%)
ARM D0/4 (0%)0/4 (0%)4/4 (100%)
ARM E0/2 (0%)0/2 (0%)2/2 (100%)
ARM F0/22 (0%)2/22 (9.1%)22/22 (100%)
ARM G0/12 (0%)1/12 (8.3%)12/12 (100%)
ARM H1/9 (11.1%)4/9 (44.4%)8/9 (88.9%)
ARM I0/3 (0%)0/3 (0%)3/3 (100%)
ARM J0/2 (0%)0/2 (0%)2/2 (100%)
ARM K0/1 (0%)0/1 (0%)1/1 (100%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventARM AARM BARM CARM DARM EARM FARM GARM HARM IARM JARM K
NAUSEAGastrointestinal disorders0/340/270/130/40/21/220/121/90/30/20/1
VOMITINGGastrointestinal disorders0/340/270/130/40/21/220/121/90/30/20/1
ATYPICAL PNEUMONIAInfections and infestations0/340/270/130/40/20/220/121/90/30/20/1
OVERDOSEInjury, poisoning and procedural complications0/340/270/130/40/20/220/121/90/30/20/1
ISCHAEMIC CEREBRAL INFARCTIONNervous system disorders0/340/270/130/40/20/220/121/90/30/20/1
ACUTE KIDNEY INJURYRenal and urinary disorders0/340/270/130/40/20/221/121/90/30/20/1
ACUTE RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders0/340/270/130/40/20/220/121/90/30/20/1
HYPONATRAEMIAMetabolism and nutrition disorders0/340/270/130/40/20/221/120/90/30/20/1
LEUKOCYTOSISBlood and lymphatic system disorders0/340/270/130/40/21/220/120/90/30/20/1
LOWER RESPIRATORY TRACT INFECTIONInfections and infestations0/340/270/130/40/21/220/120/90/30/20/1
Most frequent other events
Showing 10 of 250
Most frequent other events
EventARM AARM BARM CARM DARM EARM FARM GARM HARM IARM JARM K
ANAEMIABlood and lymphatic system disorders8/348/271/133/42/24/220/122/91/30/20/1
CONSTIPATIONGastrointestinal disorders2/341/271/130/40/24/221/122/90/30/21/1
ASTHENIAGeneral disorders8/347/271/130/42/22/221/120/90/30/20/1
FATIGUEGeneral disorders17/3414/274/134/40/214/222/126/91/31/21/1
INFLUENZA LIKE ILLNESSGeneral disorders2/341/270/130/40/20/220/120/90/30/21/1
JAUNDICEHepatobiliary disorders0/343/270/130/40/21/220/120/90/30/21/1
DRY SKINSkin and subcutaneous tissue disorders1/340/270/132/41/21/220/120/90/30/21/1
PRURITUSSkin and subcutaneous tissue disorders2/344/271/134/42/25/224/121/90/31/20/1
DRY EYEEye disorders0/340/270/130/41/20/220/120/90/30/20/1
EYE PRURITUSEye disorders0/340/270/130/41/20/220/120/90/30/20/1

Baseline characteristics

Age, Continuous
Age, Continuous(years)Arm AArm BArm CArm DArm EArm FArm GArm HArm IArm JArm KTotal
Mean59.6 ± 6.6258.0 ± 6.6661.8 ± 5.7659.8 ± 10.7878.0 ± 1.4158.3 ± 9.3562.2 ± 7.6458.0 ± 8.0057.3 ± 9.2963.5 ± 7.7850.0 ± NA59.6 ± 7.73
Sex: Female, Male
Sex: Female, Male(Participants)Arm AArm BArm CArm DArm EArm FArm GArm HArm IArm JArm KTotal
Female7450222210025
Male272384020107221104
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R Jr, Gordon F, Levitsky J, Terrault NA, Burton JR Jr, Xie W, Setze C, Badri P, Pilot-Matias T, Vilchez RA, Forns X. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014 Dec 18;371(25):2375-82. doi: 10.1056/NEJMoa1408921. Epub 2014 Nov 11. PubMed 25386767 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2013 to primary completion in Nov 2016, 44 months.

Results were first posted in Nov 2017, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2013
First posted
Feb 4, 2013
StartActual
Feb 25, 2013
Primary completionActual
Nov 2, 2016
CompletionActual
Jul 13, 2017
Results first posted
Nov 7, 2017
Last update
Nov 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01782495
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Feb 4, 2013
Start date
Feb 25, 2013
Primary completion
Nov 2, 2016
Completion
Jul 13, 2017
Results posted
Nov 7, 2017
Last update
Nov 7, 2017

Study contacts

AbbVie Inc
study director · AbbVie

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ombitasvir · Paritaprevir · Ritonavir · Dasabuvir · Ombitasvir/Paritaprevir/Ritonavir · Ribavirin

Start the discussion